Verge Genomics · Series B

We use human data and AI to develop better drugs faster

Amount

$98M

Round

Series B

Valuation

—

Announced

Dec 2021

Investors

Lead investor

Participating investors

Eli Lilly and Company Merck Global Health Innovation Fund Section 32 Vulcan Capital Threshold Ventures ALS Investment Fund Tao Capital Partners Lifeforce Capital

Notes

Reported round beyond the YC standard deal.

Other Verge Genomics rounds

Date	Round	Amount
Jan 2015	Seed	$500K	Details →